{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:15:49Z","timestamp":1788315349496,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05038-7","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:03:04Z","timestamp":1781863384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reactivation of retinopathy of prematurity after intravitreal bevacizumab: incidence, risk factors, and retreatment requirements"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-3844","authenticated-orcid":false,"given":"Cengiz","family":"G\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"\u00d6zal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Ermi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Karapapak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havvanur","family":"Bayraktar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sad\u0131k Altan","family":"\u00d6zal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"4","key":"5038_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/jama.2022.9163","volume":"328","author":"RF Soll","year":"2022","unstructured":"Soll RF. Treatment of Retinopathy of Prematurity: Moving Forward With Uncertainty. JAMA. 2022;328(4):332\u20133.","journal-title":"JAMA"},{"issue":"12","key":"5038_CR2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684\u201394.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"5038_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3\u2009+\u2009retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"5038_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.sjopt.2014.07.001","volume":"28","author":"MA Malik","year":"2014","unstructured":"Malik MA, Shukla S, Azad SV, Kaur J. Vascular endothelial growth factor (VEGF-634G\/C) polymorphism and retinopathy of prematurity: a meta-analysis. Saudi J Ophthalmol. 2014;28(4):299\u2013303.","journal-title":"Saudi J Ophthalmol"},{"issue":"7","key":"5038_CR5","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s10792-021-02198-x","volume":"42","author":"K Fadakar","year":"2022","unstructured":"Fadakar K, Mehrabi Bahar M, Riazi-Esfahani H, Azarkish A, Farahani AD, Heidari M, et al. Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence. Int Ophthalmol. 2022;42(7):2017\u201328.","journal-title":"Int Ophthalmol"},{"issue":"6","key":"5038_CR6","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C, Hausberger S, P\u00f6schl EM, Wackernagel W, et al. A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS ONE. 2015;10(6):e0129383. Published 2015 Jun 17.","journal-title":"PLoS ONE"},{"issue":"4","key":"5038_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35(4):675\u201380.","journal-title":"Retina"},{"issue":"12","key":"5038_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","volume":"129","author":"E Chang","year":"2022","unstructured":"Chang E, Josan AS, Purohit R, Patel CK, Xue K. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity. Ophthalmology. 2022;129(12):1389\u2013401.","journal-title":"Ophthalmology"},{"issue":"10","key":"5038_CR9","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021;128(10):e51\u201368.","journal-title":"Ophthalmology"},{"issue":"2","key":"5038_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10792-019-01208-3","volume":"40","author":"A Eftekhari Milani","year":"2020","unstructured":"Eftekhari Milani A, Hassanpoor N, Mousavi Mirkala M, Taheri A, Golizade A, Niyousha MR. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity. Int Ophthalmol. 2020;40(2):477\u201382.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"5038_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12886-024-03528-0","volume":"24","author":"AE Milani","year":"2024","unstructured":"Milani AE, Arasteh A, Saeedi-Maleki Z, Niyousha MR, Sahebazamani MA, Brumandpur F. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection. BMC Ophthalmol. 2024;24(1):265. Published 2024 Jun 21.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"5038_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12886-023-02886-5","volume":"23","author":"JK Cao","year":"2023","unstructured":"Cao JK, Han T, Tang HY, Zhang S, Wang ZH, Feng ZC, et al. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity. BMC Ophthalmol. 2023;23(1):137.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"5038_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","volume":"124","author":"J Feng","year":"2017","unstructured":"Feng J, Qian J, Jiang Y, Zhao M, Liang J, Yin H, et al. Efficacy of Primary Intravitreal Ranibizumab for Retinopathy of Prematurity in China. Ophthalmology. 2017;124(3):408\u20139.","journal-title":"Ophthalmology"},{"issue":"4","key":"5038_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1542\/peds.2004-1309","volume":"115","author":"BA Darlow","year":"2005","unstructured":"Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ, et al. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics. 2005;115(4):990\u20136.","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"5038_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(Suppl 1):35\u201349.","journal-title":"Pediatr Res"},{"issue":"26","key":"5038_CR16","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett ME, Penn JS. Mechanisms and management of retinopathy of Prematurity. N Engl J Med. 2012;367(26):2515\u201326.","journal-title":"N Engl J Med"},{"issue":"9","key":"5038_CR17","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","volume":"40","author":"KP Ling","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Rates and Risk Factors for Recurrence of Retinopathy of Prematurity After Laser or Intravitreal Anti-Vascular Endothelial Growth Factor Monotherapy. Retina Phila Pa. 2020;40(9):1793\u2013803.","journal-title":"Retina Phila Pa"},{"issue":"1","key":"5038_CR18","doi-asserted-by":"publisher","first-page":"15647","DOI":"10.1038\/s41598-024-66483-2","volume":"14","author":"JH Jang","year":"2024","unstructured":"Jang JH. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab. Sci Rep. 2024;14(1):15647. Published 2024 Jul 8.","journal-title":"Sci Rep"},{"issue":"4","key":"5038_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","volume":"130","author":"NA Patel","year":"2023","unstructured":"Patel NA, Acaba-Berrocal LA, Hoyek S, Fan KC, Martinez-Castellanos MA, Baumal CR, et al. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study. Ophthalmology. 2023;130(4):373\u20138.","journal-title":"Ophthalmology"},{"issue":"8","key":"5038_CR20","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"5038_CR21","first-page":"2261","volume":"41","author":"C Iwahashi","year":"2021","unstructured":"Iwahashi C, Utamura S, Kuniyoshi K, Sugioka K, Konishi Y, Wada N, et al. Factors Assoc\u0131ated with React\u0131vat\u0131on After Intrav\u0131treal Bevac\u0131zumab or Ran\u0131b\u0131zumab Therapy in Infants with Ret\u0131nopathy of Prematur\u0131ty. Ret\u0131na. 2021;41(11):2261.","journal-title":"Ret\u0131na"},{"issue":"3","key":"5038_CR22","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","volume":"58","author":"J Lyu","year":"2017","unstructured":"Lyu J, Zhang Q, Chen CL, Xu Y, Ji XD, Li JK, et al. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors. Invest Ophthalmol Vis Sci. 2017;58(3):1719\u201325.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"5038_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-020-04605-y","volume":"258","author":"MA Mart\u00ednez-Castellanos","year":"2020","unstructured":"Mart\u00ednez-Castellanos MA, Gonz\u00e1lez-H Le\u00f3n A, Romo-Aguas JC, Gonzalez-Gonzalez LA. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):767\u201372.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"5038_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12519-023-00775-x","volume":"20","author":"TM Hundscheid","year":"2024","unstructured":"Hundscheid TM, Gulden S, Almutairi MF, Barto\u0161 F, Cavallaro G, Villamor E. Sex differences in the risk of retinopathy of prematurity: a systematic review, frequentist and Bayesian meta-analysis, and meta-regression. World J Pediatr. 2024;20(4):340\u201352.","journal-title":"World J Pediatr"},{"issue":"11","key":"5038_CR25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2022.3988","volume":"140","author":"S Hoyek","year":"2022","unstructured":"Hoyek S, Peacker BL, Acaba-Berrocal LA, Al-Khersan H, Zhao Y, Hartnett ME, et al. The Male to Female Ratio in Treatment-Warranted Retinopathy of Prematurity: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022;140(11):1110\u201320.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05038-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05038-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05038-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:39:33Z","timestamp":1788313173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05038-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5038"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05038-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Ethics Committee of Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital (Approval No: E-96317027-514.10-252621450). Written informed consent was obtained from the legal guardians of all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"536"}}